Catalyst
Slingshot members are tracking this event:
Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
- Source Link:
- http://www.takeda.com/news/2016/20160527_7419.html
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TKPYY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Brentuximab Vedotin, Post-transplant Hodgkin Lymphoma, Adcetris
